Navigation Links
Transgene: Cash Position of EUR 119 Million as of September 30, 2007
Date:10/10/2007

STRASBOURG, France, October 10 /PRNewswire-FirstCall/ -- Transgene S.A. (Eurolist Paris: FR0005175080) announces that cash, cash equivalents and short term investments totaled EUR 119 million at September 30, 2007 compared to EUR 114.3 million at June 30, 2007 (unaudited figures, IAS/IFRS).

For the first nine months of 2007, cash, cash equivalents and short term investments increased by EUR 98.7 million. This was mainly due to payments received from the partnership agreement with Roche (EUR 23 million), the capital increase carried out in June and July 2007 (net proceeds: EUR 95.3 million) and cash expenditures of EUR 19.6 million.

About Transgene:

Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has one product which has completed Phase II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing. Additional information about Transgene is available on the Internet at http://www.transgene.fr.


'/>"/>
SOURCE Transgene S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. Wisconsin early-stage companies must position themselves to get capital
3. New UW position focusing on Internet security
4. Midwest holds strong position in worldwide diagnostics business
5. Doyle praises Frists new stem cell research position
6. GE promotes Milwaukee-area CEO to London position
7. Is IT leadership a position or an attitude?
8. nPoint announces new nanopositioning scanning control mode
9. Venture Investors early-stage fund grows to $115 million
10. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
11. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... New York, NY (PRWEB) , ... January 24, ... ... index (BMI), larger waist circumference, and increased serum leptin levels had a positive ... study. The study published in the International Neurourology Journal involved ...
(Date:1/24/2017)... ... 24, 2017 , ... Nor-Tech’s leading-edge demo cluster is proving ... Intel KNL. , Currently Cal Tech researchers are testing their code on ... cluster is a no-cost, no-strings opportunity for current and prospective clients to test-drive ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward Buckler, Ph.D., a research ... National Academy of Sciences Prize in Food and Agriculture Sciences. He is being ... National Academy of Sciences (NAS) Prize in Food and Agriculture Sciences was established ...
(Date:1/24/2017)... According to a new market ... Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology ... Companies, CRO) - Global Forecast to 2021", published by ... Market for the forecast period of 2016 to 2021. ... by 2021 from USD 73.3 Million in 2016, growing ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):